

**Production of galanthamine compounds used for treating e.g. neurological disorders involves oxidizing alpha beta ethylenic ketone compound into spirodienone compound**

**Patent number:** FR2826005

**Publication date:** 2002-12-20

**Inventor:** THAL CLAUDE; GUILLOU CATHERINE; BEUNARD JEAN LUC; GRAS EMMANUEL; POTIER PIERRE

**Applicant:** CENTRE NAT RECH SCIENT (FR)

**Classification:**

- **international:** C07D221/20; C07D307/91; C07D311/96; C07D317/72; C07D491/10; C07D493/10; C07D221/00; C07D307/00; C07D311/00; C07D317/00; C07D491/00; C07D493/00; (IPC1-7): C07D223/16; C07D307/91; C07D309/28; C07D317/72

- **europen:** C07D221/20C; C07D307/91D; C07D311/96; C07D317/72C; C07D491/10; C07D493/10

**Application number:** FR20010007859 20010615

**Priority number(s):** FR20010007859 20010615

**Also published as:**



WO02102803 (A1)



EP1458724 (A1)



US2005065338 (A1)

[Report a data error here](#)

**Abstract of FR2826005**

Production of galanthamine compounds (1) involves oxidizing an alpha , beta -ethylenic ketone compound (10) into a spirodienone compound (11). Production of galanthamine compounds of formula (1) involves oxidizing an alpha , beta -ethylenic ketone compound of formula (10) into a spirodienone compound of formula (11). R1 = H, and R2 = OH, or R1 + R2 = =O; R3-R5 = H, OH or 1-12C alkoxy; R6 = H, 1-12C alkyl, (CH2)nNR7R8 or (CH2)nN<+>R7R8R9; R7-R9 = H, CN, 1-4C alkyl, aryl 1-4C alkyl, arylalkenyl, 1-4C alkylcarbonyl or arylcarbonyl (all optionally alkyl, alkenyl and aryl substituted by at least one halo, OH, alkoxy, alkylthio, acyl, carboxy optionally sialified or esterified, CN, NO2, SH, mono- or di-alkylamino), or NR7R8 = heterocycl; Z = two H atoms or one O atom, and X = O, S, N, SO, SO2, NR6 or a protected amine. Independent claims are also included for compounds of formulae (8), (9), (11) and (12).

Data supplied from the **esp@cenet** database - Worldwide